Exelixis
EXEL
#2109
Rank
โ‚น632.25 B
Marketcap
โ‚น2,216
Share price
-1.53%
Change (1 day)
23.95%
Change (1 year)
Exelixis, Inc. is an American genomics-based drug discovery company and the producer of Cometriq, a treatment for medullary thyroid cancer.

Exelixis (EXEL) - Net assets

Net assets on the balance sheet as of June 2024 : โ‚น177.83 B

According to Exelixis's latest financial reports the company has โ‚น177.83 B in net assets.
A companyโ€™s net assets is the sum of its assets minus the sum of its liabilities.

Exelixis - Net assets on balance sheet (from 2001 to 2024)

Net assets by year

Year Net assets Change
2023-12-31$โ‚น188.46 B-8.47%
2022-12-31$โ‚น205.91 B24.99%
2021-12-31$โ‚น164.74 B20.08%
2020-12-31$โ‚น137.19 B14.32%
2019-12-31$โ‚น120.00 B34%
2018-12-31$โ‚น89.55 B392.2%
2017-12-31$โ‚น18.19 B199.77%
2016-12-31$โ‚น6.06 B-164.87%
2015-12-31$-โ‚น9.36 B28.75%
2014-12-31$-โ‚น7.27 B-277.52%
2013-12-31$โ‚น4.09 B-74.78%
2012-12-31$โ‚น16.23 B238.58%
2011-12-31$โ‚น4.79 B-146.84%
2010-12-31$-โ‚น10.24 B34.22%
2009-12-31$-โ‚น7.63 B172.68%
2008-12-31$-โ‚น2.8 B-182.95%
2007-12-31$โ‚น3.37 B-15.98%
2006-12-31$โ‚น4.01 B55.65%
2005-12-31$โ‚น2.57 B29.37%
2004-12-31$โ‚น1.99 B-72.94%
2003-12-31$โ‚น7.36 B-12.69%
2002-12-31$โ‚น8.43 B-26.3%
2001-12-31$โ‚น11.44 B

Net assets for similar companies or competitors

Company Net assets differencediff. Country
โ‚น1.461 T 721.92%๐Ÿ‡ฌ๐Ÿ‡ง UK
โ‚น6.564 T 3,591.58%๐Ÿ‡ซ๐Ÿ‡ท France
โ‚น3.661 T 1,959.13%๐Ÿ‡บ๐Ÿ‡ธ USA
โ‚น1.431 T 705.24%๐Ÿ‡บ๐Ÿ‡ธ USA
โ‚น497.07 B 179.52%๐Ÿ‡บ๐Ÿ‡ธ USA
โ‚น6.001 T 3,274.86%๐Ÿ‡บ๐Ÿ‡ธ USA
โ‚น7.380 T 4,050.29%๐Ÿ‡บ๐Ÿ‡ธ USA
-โ‚น58.23 M-100.03%๐Ÿ‡บ๐Ÿ‡ธ USA
โ‚น2.41 B-98.64%๐Ÿ‡บ๐Ÿ‡ธ USA